​Saros Therapeutics

Saros Therapeutics develops novel medicines to Improve Outcomes for patients with cancer. By harnessing the STING pathway with Saros' lipid nanoparticle technology, the limitations of prior STING agonists are significantly overcome. In combination with existing immunotherapies, this approach may enable a safe, effective immune response against tumors

Covira Surgical​

Focusing on a novel therapeutic alternative to infection control in a surgical setting, Covira Surgical has developed a water-Soluble prescription medication that coats the GI Tract and prevents virulent bacteria from traveling to surgical wounds.

bionode

Through developing a first-in-class smartlens system that rapidly reduces intraocular pressure in glaucoma patients, bionode seeks to enhance glaucoma therapy and improve patient outcomes. The smartlens - called IOPTx - has proven success in clinical trials,  reducing intraocular pressure in patients by 38%.

Cadenza Bio

Still in the preclinical stage, Cadenza Bio is developing orally available small molecule drugs to promote remyelination and limit inflammation in patients with Multiple Mclerosis (MS).  Their highly selective, non-steroidal agonists of Estrogen Receptor β (ERβ) harness the beneficial
neuroprotective and anti-inflammatory impacts of estrogen without risking feminization or proliferation associated with Estrogen Receptor α (ERα).

Schedule 1

Developing optimized cannabinoid medicines for FDA approval to treat large pain disorders. Schedule 1 Therapeutics (“S1Tx") is developing S1-220, an optimized CBD:THC combination to treat migraine, protected by 2 issued patents. Preclinical studies at the University of Iowa and Leiden University in the Netherlands show S1-220 to have comparable efficacy as the standard of care, with no adverse effects, in migraine and a rare form, hemiplegic migraine. S1Tx will be the first to fully characterize CBD:THC pharmacology in animal-to-human models for a platform to patent optimized treatments across therapeutic areas.
Picture